Stock A950220 NEOIMMUNETECH, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News NeoImmuneTech, Inc.

Equities

A950220

KR8840140006

End-of-day quote Korea S.E.
Other stock markets
 23:00:00 23/05/2024 BST 		5-day change 1st Jan Change
1,909 KRW +0.74% Intraday chart for NeoImmuneTech, Inc. +2.63% -5.73%
04-02 NeoImmuneTech, Inc. Announces Chief Executive Officer Changes CI
01-15 NeoImmuneTech, Inc. Appoints Luke Oh as President CI

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
NeoImmuneTech, Inc. Announces Chief Executive Officer Changes
CI
NeoImmuneTech, Inc. Appoints Luke Oh as President
CI
Fda Grants Orphan Drug Designation to Neoimmunetech's Nt-I7 for the Treatment of Acute Radiation Syndrome
CI
Neoimmunetech, Inc. Appoints Benny J. Chen and Su-Hyung Park to Its Scientific Advisory Board
CI
NeoImmuneTech, Inc. to Partner with U.S. National Institute of Allergy and Infectious Diseases, National Institutes of Health for Drug Development in Acute Radiation Syndrome
CI
New Evidence of NeoImmuneTech's NT-I7 Clinical Efficacy in Combination with Pembrolizumab in Relapsed/Refractory (R/R) Gastrointestinal Tumors
CI
NeoImmuneTech, Inc. Appoints New Members to its Scientific Advisory Board
CI
NeoImmuneTech's NT-I7 Enhances CAR-T Cell Expansion, Persistence and Anti-tumor Activity
CI
NeoImmuneTech, Inc.'s Lead Asset NT-I7 (efineptakin alfa) Shows Preliminary Anticancer Activity in Combination with Check-Point Inhibitors
CI
Neoimmunetech Demonstrates Nt-I7’S Broad Combination Potential with Immune Checkpoint Inhibitors and Immunocytokine At Aacr 2022
CI
NeoImmuneTech, Inc. Announces First Patient Dosed in Phase 2 Study of NT-I7 (efineptakin alfa) with PD-L1 Checkpoint Inhibitor in High-Risk Skin Cancers
CI
NeoImmuneTech, Inc. Announces the Publication of Preclinical Data Evaluating Lead Asset NT-I7
CI
South Korea's Secondary Stock Market Adds Largest Number of New Tech IPOs in 2021
MT
An unknown buyer agreed to acquire a 5.1% stake in NeoImmuneTech, Inc. from SillaJen, Inc. for KRW 10.1 billion.
CI
NeoImmuneTech, Inc. announced that it has received $4.7 million in funding from Hefei SPARK Venture Capital Management Co., Ltd., Kindstar Global Technology, Inc.
CI
NeoImmuneTech, Inc. Presents Phase 1 Study Data at Society for Neuro-Oncology Annual Meeting
CI
NeoImmuneTech, Inc. Presents Data in Three Posters At Society for Immunotherapy of Cancer Annual Meeting
CI
NeoimmuneTech Announces First Patient Dosed in Phase 2 Study of NT-I7 (Efineptakin Alfa) in Combination with PD-L1 Checkpoint Inhibitor in Frontline Locally Advanced or Metastatic Non-Small Cell Lung Cancer
CI
NeoImmuneTech Announces First Patient Dosed in Phase 1b Study of NT-I7 (efineptakin alfa) and Kymriah® (tisagenlecleucel) in Relapsed/Refractory Large B-Cell Lymphoma
CI
NeoImmuneTech to Present Three Posters at Society for Immunotherapy of Cancer Annual Meeting
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. A950220 Stock
  4. News NeoImmuneTech, Inc.